The genital warts (condyloma acuminatum) market is predicted to grow from its current value of US$ 1.87 billion in 2023 to US$ 3 billion by 2033, with a CAGR of 4.84%. Due to the anticipated introduction of novel medications, the dynamics of the genital warts market are anticipated to shift in the upcoming years. Drugs for genital warts are being developed by important firms including Tamir Biotechnology (Orgenesis), Verrica Pharmaceuticals, Novan Inc., and others. Additionally, effective vaccination campaigns that are widely publicised have raised public awareness of vaccinations and their benefits, which has led to a rise in immunisation rates. Additionally, a decreased incidence of genital warts has been associated with higher vaccination rates.
The global market is expected to benefit from government initiatives and increasing financing for cancer research. The rising expenditure on R&D connected with oncologic disorders, on the other hand, presents significant potential growth for the market. For instance, the 2010 Affordable Care act provides the human papillomavirus vaccine, HPV testing, and Pap testing for most of the covered patients. Although the Healthy People 2020 goal in the U.S. sets a target of 80% vaccination coverage against HPV, a 2016 national survey projected that only 50% of girls have completed all doses.
Get Your Report Sample To Gain Comprehensive Insights! https://www.futuremarketinsights.com/reports/sample/rep-gb-16211
In July 2014, Paladin Labs Inc., a subsidiary of Endo International plc., a pharmaceutical company declared the launch of Veregen (sinecatechins) Ointment, 10%, a topical treatment for external genital and perianal warts (condylomata acuminata) in immunocompetent patients aged 18 years and older. Furthermore, continuous innovation in healthcare sector increased consumer awareness and investments in medical infrastructure. Emerging and less developed countries are likely to produce several opportunities that will have an influence on market growth during the forecast period.
However, the lack of public awareness and understanding about the accessibility, usage of vaccines, and HPV, along with growing concerns about the side effects of therapies for a longer period and expensive treatment alternatives are expected to act as significant restraining factors. There is a high unmet need for targeted drugs with enhanced clinical profile at reduced costs and convenient administration schedule. However, growing R&D expenditure on oncologic diseases offers a promising future for the market in the foreseeable future.
Key Takeaways:
- FMI estimates the Genital warts market to achieve valuation of US$ 3 Billion by 2033.
- North America is set to dominate the market with 40% market share.
- Hospital pharmacies are estimated to rule the segment by accounting highest share on the basis of distribution channel.
- Dominating genital warts companies such as Verrica Pharmaceuticals, Tamir Biotechnology, Novan Inc., and others are developing novel genital warts drugs that can be available in the genital warts market in the forthcoming years.
- The prevalent genital warts therapies in the pipeline include VP-102, Ranpirnase (RanTop), Berdazimer sodium (SB 206), and others.
- The increase in genital warts market size is a consequence of the expected approval of emerging therapies in the major markets during the forecast period.
- APAC is projected to be fastest growing industry for Genital warps treatment.
Get The Information You Need By Connecting With Our Analyst! https://www.futuremarketinsights.com/ask-question/rep-gb-16211
Competitive Landscape:
Key players in the Genital Warts market are: Verrica Pharmaceuticals, Tamir Biotechnology, Novan Inc., Medicis Pharmaceuticals, Aresus Pharma, AbbVie, Sanofi S.A., AbbVie Inc, Perrigo Company PLC, Glenmark Pharmaceuticals. Some key developments in this market are:
- In 2019, GenieMD, a global provider of telemedicine services, developed their telemedicine app iVisit that would allow patients to be diagnosed and treated for genital warts via virtual visit with the physician.
- For instance, in August 2018, Oceanside Pharmaceuticals, a company which delivers pharmaceutical services, created an authorized generic version of Bausch Health’s Zyclara (imiquimod) 3.75% cream pump. Zyclara (imiquimod) 3.75% is indicated for the topical treatment of external genital and perianal warts/condyloma acuminata (EGW) in patients of age 12 years or older.
- In June 2020, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., had announced the U.S. FDA approval for GARDASIL9 (Human Papillomavirus 9-valent Vaccine, Recombinant) for the prevention of HPV-related cervical, vaginal, vulvar, anal, oropharyngeal, and other head and neck cancers. The FDA approval received would result in addressing the unmet clinical needs for the patients, increased distribution of the vaccine in hospitals and cancer research institutes, for the rise in product sales.
Empower Your Business with Customization: Discover the Strategies in Our New Report! https://www.futuremarketinsights.com/customization-available/rep-gb-16211
Key Segments Profiled in the Genital Warts Market Industry survey:
Genital Warts Market by Treatment:
- Chemical Treatment
- Ablative Treatment
- Preventive Treatment
- Other Treatments
Genital Warts Market by Distribution Channel:
- Hospital Pharmacies
- Retail pharmacies
- Online Pharmacies
Genital Warts Market by Region:
- North America
- Latin America
- Europe
- South Asia and Pacific
- East Asia
- Middle East & Africa (MEA)
Unlock Exclusive Market Segments Insights: Buy Now! https://www.futuremarketinsights.com/checkout/16211
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
